Congress Presentations
Stay informed about the latest scientific and medical research from Axsome.
American Society of Clinical Psychopharmacology (ASCP)
Miami Beach, FL | May 28 - 31, 2024
AXS-05 | Alzheimer’s Disease Agitation
Clinical Profile of AXS-05 (Dextromethorphan-Bupropion) in Treating Alzheimer’s Disease Agitation: Results From The Phase 2/3 Development Program
AXS-05 | Alzheimer’s Disease Agitation
Dr. Jeffrey L. Cummings, MD, ScD describes the "Clinical Profile of AXS-05 (Dextromethorphan-Bupropion) in Treating Alzheimer’s Disease Agitation: Results From The Phase 2/3 Development Program" ASCP 2024 poster
AXS-05 | Major Depressive Disorder
Real-World Auvelity® (AXS-05) Patient Characteristics in Major Depressive Disorder
AXS-05 | Alzheimer’s Disease Agitation
Effects of AXS-05 (Dextromethorphan-Bupropion) in Improving Anhedonia and Interest-Activity Symptoms of MDD and the Associated Improvements in Functional Impairment
AXS-05 | Major Depressive Disorder
Dr. Andrew Muzyk, PharmD describes the "Real-World Auvelity® (AXS-05) Patient Characteristics in Major Depressive Disorder" ASCP 2024 poster
AXS-05 | Alzheimer’s Disease Agitation
Dr. Roger McIntyre, MD, FRCPC describes the "Effects of AXS-05 (Dextromethorphan-Bupropion) in Improving Anhedonia and Interest-Activity Symptoms of MDD and the Associated Improvements in Functional Impairment" ASCP 2024 poster
Solriamfetol | Excessive Daytime Sleepiness
Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-Controlled Study of Sleep Apnea Participants (SHARP)
Solriamfetol | Excessive Daytime Sleepiness
Dr. David Gozal, MD, MBA describes the "Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-Controlled Study of Sleep Apnea Participants (SHARP)" ASCP 2024 poster
